The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Acute Coronary Syndrome
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
-
Advanced Cardiovascular, LLC, Alexander City, Alabama, United States, 35010
SORRA Research, Birmingham, Alabama, United States, 35203
Ascension St. Vincent's Health System, Birmingham, Alabama, United States, 35205
IMC-Diagnostic and Medical Clinic, Mobile, Alabama, United States, 36604
Cardiology Associates of Mobile Inc, Mobile, Alabama, United States, 36608
Mercy Gilbert Medical Center, Gilbert, Arizona, United States, 85297
Valleywise Health Medical Center, Phoenix, Arizona, United States, 85008
HonorHealth Neurology, Scottsdale, Arizona, United States, 85258
Arkansas Heart Hospital, Little Rock, Arkansas, United States, 72211
Bakersfield Memorial Hospital, Bakersfield, California, United States, 93306
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Janssen Research & Development, LLC,
Janssen Research & Development, LLC Clinical Trial, STUDY_DIRECTOR, Janssen Research & Development, LLC
2026-12-09